SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Haozhe Li, Wu Hong, Chen Zhang, Zhiguo Wu, Zuowei Wang, Chenmei Yuan, Zezhi Li, Jia Huang, Zhiguang Lin, Yiru Fang, IL-23 and TGF-β1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode, Journal of Affective Disorders, 2015, 174, 361

    CrossRef

  2. 2
    Subramanian Karthick, Shivanand Kattimani, Ravi Philip Rajkumar, Balaji Bharadwaj, Siddharth Sarkar, Long term course of bipolar I disorder in India: Using retrospective life chart method, Journal of Affective Disorders, 2015, 173, 255

    CrossRef

  3. 3
    Tammas Kelly, A favorable risk-benefit analysis of high dose thyroid for treatment of bipolar disorders with regard to osteoporosis, Journal of Affective Disorders, 2014, 166, 353

    CrossRef

  4. 4
    Jeremy D. Coplan, Srinath Gopinath, Chadi G. Abdallah, Benjamin R. Berry, A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy, Frontiers in Behavioral Neuroscience, 2014, 8,

    CrossRef

  5. 5
    Kee Jeong Park, Seunghyun Shon, Hyun-Jeong Lee, Yeonho Joo, Eric A. Youngstrom, Hyo-Won Kim, Antidepressant-Emergent Mood Switch in Korean Adolescents With Mood Disorder, Clinical Neuropharmacology, 2014, 37, 6, 177

    CrossRef

  6. 6
    Kesavan Muralidharan, Jan-Marie Kozicky, Joana Bücker, Leonardo E. Silveira, Ivan J. Torres, Lakshmi N. Yatham, Are cognitive deficits similar in remitted early bipolar I disorder patients treated with lithium or valproate? Data from the STOP-EM study, European Neuropsychopharmacology, 2014,

    CrossRef

  7. 7
    Zuowei Wang, Zezhi Li, Keming Gao, Yiru Fang, Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: a meta-analysis, BMC Psychiatry, 2014, 14, 1

    CrossRef

  8. 8
    Ajeet B Singh, Andrew A Nierenberg, Lakshmi N Yatham, Michael Berk, Atypical antipsychotic agents; Peas in a pod or chalk and cheese?, BMC Medicine, 2014, 12, 1, 126

    CrossRef

  9. 9
    Ludovic Samalin, Pierre-Michel Llorca, Avis critique sur la place du lithium dans les recommandations professionnelles sur la prise en charge du trouble bipolaire, Annales Médico-psychologiques, revue psychiatrique, 2014, 172, 3, 177

    CrossRef

  10. 10
    David J. Bond, Tae Hyon Ha, Donna J. Lang, Wayne Su, Ivan J. Torres, William G. Honer, Raymond W. Lam, Lakshmi N. Yatham, Body Mass Index–Related Regional Gray and White Matter Volume Reductions in First-Episode Mania Patients, Biological Psychiatry, 2014, 76, 2, 138

    CrossRef

  11. 11
    Lucio Oldani, A. Carlo Altamura, Mohamed Abdelghani, Allan H. Young, Brain stimulation treatments in bipolar disorder: A review of the current literature, The World Journal of Biological Psychiatry, 2014, 1

    CrossRef

  12. 12
    Michel Bourin, Florence Thibaut, Can Antipsychotic Agents be Considered as Real Antimanic Treatments?, Frontiers in Psychiatry, 2014, 5,

    CrossRef

  13. 13
    Soham Rej, Dominique Elie, Istvan Mucsi, Karl J. Looper, Marilyn Segal, Chronic Kidney Disease in Lithium-Treated Older Adults: A Review of Epidemiology, Mechanisms, and Implications for the Treatment of Late-Life Mood Disorders, Drugs & Aging, 2014,

    CrossRef

  14. 14
    Heinz Grunze, Jean Michel Azorin, Clinical decision making in the treatment of mixed states, The World Journal of Biological Psychiatry, 2014, 15, 5, 355

    CrossRef

  15. 15
    Adam Bayes, Gordon Parker, Kathryn Fletcher, Clinical differentiation of bipolar II disorder from borderline personality disorder, Current Opinion in Psychiatry, 2014, 27, 1, 14

    CrossRef

  16. 16
    Gustavo H. Vázquez, Ross J. Baldessarini, Leonardo Tondo, CO-OCCURRENCE OF ANXIETY AND BIPOLAR DISORDERS: CLINICAL AND THERAPEUTIC OVERVIEW, Depression and Anxiety, 2014, 31, 3
  17. 17
    Sylvia A. Mackala, Ivan J. Torres, Jan Kozicky, Erin E. Michalak, Lakshmi N. Yatham, Cognitive performance and quality of life early in the course of bipolar disorder, Journal of Affective Disorders, 2014, 168, 119

    CrossRef

  18. 18
    Sagar V Parikh, Lisa D Hawke, Vytas Velyvis, Ari Zaretsky, Serge Beaulieu, Irene Patelis-Siotis, Glenda MacQueen, L Trevor Young, Lakshmi N Yatham, Pablo Cervantes, Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder, Bipolar Disorders, 2014, 16, 8
  19. 19
    Tomofumi Miura, Hisashi Noma, Toshi A Furukawa, Hiroshi Mitsuyasu, Shiro Tanaka, Sarah Stockton, Georgia Salanti, Keisuke Motomura, Satomi Shimano-Katsuki, Stefan Leucht, Andrea Cipriani, John R Geddes, Shigenobu Kanba, Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis, The Lancet Psychiatry, 2014, 1, 5, 351

    CrossRef

  20. 20
    Alexandra Kutzelnigg, Martin Kopeinig, Chih-Ken Chen, Ágnes Fábián, María Pujol-Luna, Young-chul Shin, Tamás Treuer, Yulia D’yachkova, Claudia Deix, Siegfried Kasper, Dagmar Doby, Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study, International Journal of Bipolar Disorders, 2014, 2, 1, 13

    CrossRef

  21. 21
    Laura Sawyer, Jean-Michel Azorin, Stacey Chang, Claudia Rinciog, Alice Guiraud-Diawara, Caroline Marre, Karina Hansen, Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes, Journal of Medical Economics, 2014, 17, 7, 508

    CrossRef

  22. 22
    Izabela Guimarães Barbosa, Moisés Evandro Bauer, Rodrigo Machado-Vieira, Antonio Lucio Teixeira, Cytokines in Bipolar Disorder: Paving the Way for Neuroprogression, Neural Plasticity, 2014, 2014, 1

    CrossRef

  23. 23
    R.M. Hirschfeld, Differential diagnosis of bipolar disorder and major depressive disorder, Journal of Affective Disorders, 2014, 169, S12

    CrossRef

  24. 24
    Man Wang, Jian-hua Tong, De-sheng Huang, Gang Zhu, Guang-ming Liang, Hong Du, Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study, Psychopharmacology, 2014, 231, 14, 2811

    CrossRef

  25. 25
    Paul A Keedwell, Allan H Young, Emerging drugs for bipolar depression: an update, Expert Opinion on Emerging Drugs, 2014, 19, 1, 25

    CrossRef

  26. 26
    Sung-Wan Kim, Lesley Berk, Jayashri Kulkarni, Seetal Dodd, Anthony de Castella, Paul B Fitzgerald, G. Paul Amminger, Michael Berk, Impact of comorbid anxiety disorders and obsessive–compulsive disorder on 24-month clinical outcomes of bipolar I disorder, Journal of Affective Disorders, 2014, 166, 243

    CrossRef

  27. 27
    S. Kittel-Schneider, T. Wobrock, H. Scherk, T. Schneider-Axmann, S. Trost, D. Zilles, C. Wolf, A. Schmitt, B. Malchow, A. Hasan, M. Backens, W. Reith, P. Falkai, O. Gruber, A. Reif, Influence of DGKH variants on amygdala volume in patients with bipolar affective disorder and schizophrenia, European Archives of Psychiatry and Clinical Neuroscience, 2014,

    CrossRef

  28. 28
    Soham Rej, Bandar AlAqeel, Marilyn Segal, Nancy C.P. Low, Istvan Mucsi, Christina Holcroft, Karl Looper, Is environmental temperature related to renal symptoms, serum lithium levels, and other laboratory test results in current lithium users?, Human Psychopharmacology: Clinical and Experimental, 2014, 29, 4
  29. 29
    J L Wang, S M Shamah, A X Sun, I D Waldman, S J Haggarty, R H Perlis, Label-free, live optical imaging of reprogrammed bipolar disorder patient-derived cells reveals a functional correlate of lithium responsiveness, Translational Psychiatry, 2014, 4, 8, e428

    CrossRef

  30. 30
    Rafael T. de Sousa, Miyuki Uno, Marcus V. Zanetti, Sueli M.O. Shinjo, Geraldo F. Busatto, Wagner F. Gattaz, Sueli K.N. Marie, Rodrigo Machado-Vieira, Leukocyte mitochondrial DNA copy number in bipolar disorder, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 32

    CrossRef

  31. 31
    Marcio Gerhardt Soeiro-de-Souza, Antonio L. Teixeira, Elvis C. Mateo, Marcus V. Zanetti, Flavia G. Rodrigues, Vanessa J. de Paula, Julia F. Bezerra, Ricardo A. Moreno, Wagner F. Gattaz, Rodrigo Machado-Vieira, Leukocyte telomerase activity and antidepressant efficacy in bipolar disorder, European Neuropsychopharmacology, 2014, 24, 7, 1139

    CrossRef

  32. 32
    Márcio Gerhardt Soeiro-de-Souza, Philip W. Gold, Andre R. Brunoni, Rafael T. de Sousa, Marcus V. Zanetti, André F. Carvalho, Wagner Farid Gattaz, Rodrigo Machado-Vieira, Antônio Lúcio Teixeira, Lithium Decreases Plasma Adiponectin Levels in Bipolar Depression, Neuroscience Letters, 2014, 564, 111

    CrossRef

  33. 33
    Soham Rej, Serge Beaulieu, Marilyn Segal, Nancy C. P. Low, Istvan Mucsi, Christina Holcroft, Kenneth Shulman, Karl J. Looper, Lithium Dosing and Serum Concentrations Across the Age Spectrum: From Early Adulthood to the Tenth Decade of Life, Drugs & Aging, 2014, 31, 12, 911

    CrossRef

  34. 34
    Genevieve Curran, Arun Ravindran, Lithium for bipolar disorder: a review of the recent literature, Expert Review of Neurotherapeutics, 2014, 14, 9, 1079

    CrossRef

  35. 35
    David E. Kemp, Managing the side effects associated with commonly used treatments for bipolar depression, Journal of Affective Disorders, 2014, 169, S34

    CrossRef

  36. 36
    Francisco Romo-Nava, Dení Alvarez-Icaza González, Ana Fresán-Orellana, Ricardo Saracco Alvarez, Claudia Becerra-Palars, Julia Moreno, Martha P Ontiveros Uribe, Carlos Berlanga, Gerhard Heinze, Ruud M Buijs, Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial, Bipolar Disorders, 2014, 16, 4
  37. You have free access to this content37
    Alan C. Swann, Non-pharmacological and pharmacological treatments act on the same brain, World Psychiatry, 2014, 13, 3
  38. 38
    Pei-Yin Pan, Meei-Shyuan Lee, Miao-Chi Lo, En-Lin Yang, Chin-Bin Yeh, Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study, BMC Psychiatry, 2014, 14, 1, 145

    CrossRef

  39. 39
    Leonardo Tondo, Gustavo H. Vázquez, Ross J. Baldessarini, Options for Pharmacological Treatment of Refractory Bipolar Depression, Current Psychiatry Reports, 2014, 16, 2

    CrossRef

  40. 40
    Rafael T. de Sousa, Carlos A. Zarate, Marcus V. Zanetti, Alana C. Costa, Leda L. Talib, Wagner F. Gattaz, Rodrigo Machado-Vieira, Oxidative stress in early stage Bipolar Disorder and the association with response to lithium, Journal of Psychiatric Research, 2014, 50, 36

    CrossRef

  41. 41
    Christopher J Miller, Mingfei Li, Robert B Penfold, Austin F Lee, Eric G Smith, David N Osser, Laura Bajor, Mark S Bauer, Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior, BMC Psychiatry, 2014, 14, 1, 339

    CrossRef

  42. 42
    Luca Degli Esposti, Diego Sangiorgi, Claudio Mencacci, Edoardo Spina, Carlotta Pasina, Marianna Alacqua, Flore la Tour, Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study, BMC Psychiatry, 2014, 14, 1

    CrossRef

  43. 43
    S. Köhler, M. Bauer, T. Bschor, Pharmakologische Behandlung der bipolaren Depression, Der Nervenarzt, 2014, 85, 9, 1075

    CrossRef

  44. 44
    Daniel Schuepbach, Erich Seifritz, Pharmakotherapie der bipolaren Störungen und der Manie, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 2014, 62, 4, 243

    CrossRef

  45. 45
    Julia Volkert, Kathrin C Zierhut, Miriam A Schiele, Martina Wenzel, Juliane Kopf, Sarah Kittel-Schneider, Andreas Reif, Predominant polarity in bipolar disorder and validation of the polarity index in a German sample, BMC Psychiatry, 2014, 14, 1

    CrossRef

  46. 46
    Takeshi Inoue, Yoshifumi Inagaki, Toshifumi Kimura, Osamu Shirakawa, Prevalence and predictors of bipolar disorders in patients with a major depressive episode: The Japanese epidemiological trial with latest measure of bipolar disorder (JET-LMBP), Journal of Affective Disorders, 2014,

    CrossRef

  47. 47
    Johannes Vetter, Laura Bohleber, Heinz Böker, Psycho- und soziotherapeutische Interventionen bei bipolaren affektiven Störungen: Review, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 2014, 62, 4, 265

    CrossRef

  48. 48
    Ludovic Samalin, Aurore Tremey, Pierre-Michel Llorca, Quetiapine extended release for the treatment of bipolar disorder, Expert Review of Neurotherapeutics, 2014, 14, 9, 987

    CrossRef

  49. 49
    Carley J Pope, Verinder Sharma, Dwight Mazmanian, Recognition, diagnosis and treatment of postpartum bipolar depression, Expert Review of Neurotherapeutics, 2014, 14, 1, 19

    CrossRef

  50. 50
    Jeffrey J. Rakofsky, Boadie W. Dunlop, REVIEW OF NUTRITIONAL SUPPLEMENTS FOR THE TREATMENT OF BIPOLAR DEPRESSION, Depression and Anxiety, 2014, 31, 5
  51. 51
    Carol A. Janney, Mark S. Bauer, Amy M. Kilbourne, Self-Management and Bipolar Disorder–A Clinician’s Guide to the Literature 2011-2014, Current Psychiatry Reports, 2014, 16, 9

    CrossRef

  52. 52
    Joana Bücker, Swetha Popuri, Kesavan Muralidharan, Jan-Marie Kozicky, Heather A. Baitz, William G. Honer, Ivan J. Torres, Lakshmi N. Yatham, Sex differences in cognitive functioning in patients with bipolar disorder who recently recovered from a first episode of mania: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM), Journal of Affective Disorders, 2014, 155, 162

    CrossRef

  53. 53
    I. Grande, P. V. Magalhães, I. Chendo, L. Stertz, B. Panizutti, G. D. Colpo, A. R. Rosa, C. S. Gama, F. Kapczinski, E. Vieta, Staging bipolar disorder: clinical, biochemical, and functional correlates, Acta Psychiatrica Scandinavica, 2014, 129, 6
  54. 54
    Rafael T de Sousa, Rodrigo Machado-Vieira, Carlos A Zarate, Husseini K Manji, Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder, Expert Opinion on Therapeutic Targets, 2014, 18, 10, 1131

    CrossRef

  55. 55
    Cecilio Álamo, Francisco López-Muñoz, Pilar García-García, The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder, Expert Review of Neurotherapeutics, 2014, 14, 6, 593

    CrossRef

  56. 56
    Massimiliano Buoli, Alice Caldiroli, Elisabetta Caletti, Elisa Zugno, A. Carlo Altamura, The impact of mood episodes and duration of illness on cognition in bipolar disorder, Comprehensive Psychiatry, 2014, 55, 7, 1561

    CrossRef

  57. 57
    Andre F. Carvalho, Michael Berk, Thomas N. Hyphantis, Roger S. McIntyre, The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives, Psychotherapy and Psychosomatics, 2014, 83, 2, 70

    CrossRef

  58. 58
    Othman Mohammad, David N. Osser, The Psychopharmacology Algorithm Project at the Harvard South Shore Program, Harvard Review of Psychiatry, 2014, 22, 5, 274

    CrossRef

  59. 59
    Juan D. Barbero, Gemma Garcia-Parés, Marta Llorens, Meritxell Tost, Jesús Cobo, Diego Palao, Javier Labad, Thyroglobulin antibodies and risk of readmission at one year in subjects with bipolar disorder, Psychiatry Research, 2014, 219, 1, 109

    CrossRef

  60. 60
    Bernardo Dell’Osso, Laura Cremaschi, Maria Carlotta Palazzo, Gregorio Spagnolin, Alma Cattaneo, Benedetta Grancini, Matteo Maggi, Alfredo Carlo Altamura, Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series, Expert Opinion on Drug Safety, 2014, 13, 9, 1199

    CrossRef

  61. 61
    Emeline Marlinge, Frank Bellivier, Josselin Houenou, White matter alterations in bipolar disorder: potential for drug discovery and development, Bipolar Disorders, 2014, 16, 2
  62. 62
    Rif S. El-Mallakh, A worldwide yearly survey of new data in adverse drug reactions, 2014,

    CrossRef

  63. 63
    Minoru Takeshima, Takashi Oka, Association between the so-called “activation syndrome” and bipolar II disorder, a related disorder, and bipolar suggestive features in outpatients with depression, Journal of Affective Disorders, 2013, 151, 1, 196

    CrossRef

  64. 64
    Massimiliano Buoli, Cristina Dobrea, Alice Caldiroli, Laura Cremaschi, A. Carlo Altamura, Augmentative Asenapine in a Recurrent Manic Catatonic Patient with Partial Response to Clozapine, Case Reports in Psychiatry, 2013, 2013, 1

    CrossRef

  65. 65
    Megan J Ehret, William Baker, Hannah O’Neill, BDNFVal66Met polymorphism and lithium response: a meta-analysis, Personalized Medicine, 2013, 10, 8, 777

    CrossRef

  66. 66
    Kathryn Fletcher, Gordon Parker, Vijaya Manicavasagar, Behavioral Activation System (BAS) differences in bipolar I and II disorder, Journal of Affective Disorders, 2013, 151, 1, 121

    CrossRef

  67. 67
    Se Hyun Kim, Hyun Sook Yu, Hong Guen Park, Yong Min Ahn, Yong Sik Kim, Young Han Lee, Kyooseob Ha, Soon Young Shin, Egr1 regulates lithium-induced transcription of the Period 2 (PER2) gene, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013, 1832, 12, 1969

    CrossRef

  68. 68
    Umberto Albert, David De Cori, Andrea Aguglia, Francesca Barbaro, Fabio Lanfranco, Filippo Bogetto, Giuseppe Maina, Lithium-associated hyperparathyroidism and hypercalcaemia: A case-control cross-sectional study, Journal of Affective Disorders, 2013, 151, 2, 786

    CrossRef

  69. 69
    Eduard Vieta, Marc Valentí, Mixed states in DSM-5: Implications for clinical care, education, and research, Journal of Affective Disorders, 2013, 148, 1, 28

    CrossRef

  70. 70
    Giovanni Severino, Alessio Squassina, Marta Costa, Claudia Pisanu, Stefano Calza, Martin Alda, Maria Del Zompo, Mirko Manchia, Pharmacogenomics of bipolar disorder, Pharmacogenomics, 2013, 14, 6, 655

    CrossRef

  71. 71
    Eduard Vieta, Marc Valentí, Pharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis, CNS Drugs, 2013, 27, 7, 515

    CrossRef

  72. 72
    J.-M. Azorin, R. Belzeaux, M. Cermolacce, A. Kaladjian, N. Corréard, D. Dassa, M. Dubois, M. Maurel, J.A. Micoulaud Franchi, D. Pringuey, E. Fakra, Recommandations sur le traitement des épisodes mixtes dans les guidelines actuels, L'Encéphale, 2013, 39, 185

    CrossRef

  73. 73
    Ayal Schaffer, Sagar V Parikh, Sidney H Kennedy, Roumen Milev, Benicio N Frey, Benjamin I Goldstein, Serge Beaulieu, Martin Alda, Claire O'Donovan, Glenda MacQueen, Roger S McIntyre, Verinder Sharma, Arun Ravindran, L Trevor Young, David J Bond, Raymond W Lam, Lakshmi N Yatham, Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines, Bipolar Disorders, 2013, 15, 3
  74. 74
    P. Grof, B. Müller-Oerlinghausen, S3-Leitlinien zu bipolaren Störungen sind zeitgerechte und wichtige Instrumente für die klinische Praxis. Kontra, Der Nervenarzt, 2013, 84, 7, 876

    CrossRef

  75. 75
    M. Köster, R. Grohmann, R. R. Engel, M. A. Nitsche, E. Rüther, D. Degner, Seizures during antidepressant treatment in psychiatric inpatients—results from the transnational pharmacovigilance project “Arzneimittelsicherheit in der Psychiatrie” (AMSP) 1993–2008, Psychopharmacology, 2013, 230, 2, 191

    CrossRef

  76. 76
    Anne Berghöfer, Martin Alda, Mazda Adli, Christopher Baethge, Michael Bauer, Tom Bschor, Paul Grof, Bruno Müller-Oerlinghausen, Janusz K Rybakowski, Alexandra Suwalska, Andrea Pfennig, Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients, International Journal of Bipolar Disorders, 2013, 1, 1, 11

    CrossRef

  77. 77
    Traci L. Turner, The use of antipsychotics in maintenance treatment of bipolar disorder, Mental Health Clinician, 2013, 2, 12, 412

    CrossRef

  78. 78
    John R Geddes, David J Miklowitz, Treatment of bipolar disorder, The Lancet, 2013, 381, 9878, 1672

    CrossRef